Tissue equivalent transplantation in the treatment of certain skin injuries

Abstract

Chronic ulcers are a common and socially significant problem worldwide. Autodermoplasty is the gold standard treatment for chronic ulcers. However, it is not always possible to perform this surgical procedure for a rather large group of patients, due to some reasons, which include high risk of autodermotransplant rejection, lack of donor material, and patient’s unwillingness to undergo surgery with an often unpredictable result. A potential solution to the problem is to use skin equivalents from allogeneic donor material. The use of allogeneic (donor) human cells makes it possible to fill the deficit of the patient’s donor resources and close wound without causing additional injury to the patient. This paper provides an overview of the application of foreign and domestic biomedical cell products in clinical trials and real clinical practice. We draw conclusions on the efficiency of the considered biomedical cell products in the treatment of chronic ulcers, evaluate the conducted research, and make recommendations on the most efficient use of allogeneic dermatotropic biomedical cell products.